Effect of SGLT-2 inhibitors on hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus and MASLD. Uzbekistan Open Conference, [S. l.], n. 1, 2026. DOI: 10.57033/RSSPMCE-2026-00022. Disponível em: https://openconf.uz/conf/article/view/110. Acesso em: 21 jun. 2026.